PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

BenzingaNov 20 08:38 ET

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test

PR NewswireNov 20 07:56 ET

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR NewswireNov 18 08:15 ET

Cantor Fitzgerald Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Cuts Target Price to $2

Moomoo NewsNov 15 12:33 ET · Ratings

Express News | Cantor Fitzgerald Maintains Overweight on Lucid Diagnostics, Lowers Price Target to $2

BenzingaNov 15 09:52 ET

Maxim Group Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 14 15:31 ET · Ratings